导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.45% | 988/4773 |
| 近一周 | -2.47% | 2276/5462 |
| 近一月 | -1.96% | 1104/5421 |
| 近一季 | 1.17% | 576/5209 |
| 近半年 | 7.45% | 617/4920 |
| 近一年 | 8.51% | 1181/4366 |
| 近两年 | 44.00% | 1690/2954 |
| 近三年 | 30.63% | 1029/2253 |
| 成立以来 | 94.52% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.94% 3979/4961 |
18.05% 1423/5312 |
- - |
- - |
| 2025 | 16.29% 2468/4813 |
-0.14% 2081/3635 |
0.13% 2756/4076 |
15.84% 2767/4524 |
0.40% 2014/4813 |
| 2024 | 11.87% 1292/3463 |
8.60% 178/2808 |
-0.66% 813/3014 |
12.50% 2329/3129 |
-7.82% 2799/3463 |
| 2023 | -7.15% 895/2656 |
2.34% 1372/2280 |
-5.18% 1394/2385 |
0.72% 349/2515 |
-5.01% 1233/2655 |
| 2022 | -18.57% 728/2207 |
-13.00% 681/1919 |
8.53% 357/2016 |
-14.88% 1166/2113 |
1.31% 1311/2208 |
| 2021 | -13.20% 1134/1822 |
-2.58% 671/1255 |
-2.02% 1190/1330 |
-10.40% 1223/1466 |
1.49% 906/1822 |
| 2020 | 43.46% 243/1250 |
-7.79% 572/1028 |
15.30% 509/1067 |
14.72% 261/1164 |
17.61% 116/1184 |
| 2019 | 50.66% 99/1092 |
30.83% 229/739 |
7.23% 11/788 |
2.32% 307/850 |
4.96% 761/918 |
| 2018 | -16.84% 114/834 |
- - |
-2.26% 64/631 |
4.25% 74/660 |
-14.01% 570/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达上证50增强C VS. 长安沪深300非周期A(740101) |